Bb Biotech Ag Picked Radius Health Inc. (NASDAQ:RDUS) Shares

0
381

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Radius Health Inc. (NASDAQ:RDUS) reported that Bb Biotech Ag has picked up 4,718,922 of common stock as of 2017-03-22.

The acquisition brings the aggregate amount owned by Bb Biotech Ag to a total of 4,718,922 representing a 10.9% stake in the company.

For those not familiar with the company, Radius Health, Inc. is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. Its clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.

A glance at Radius Health Inc. (NASDAQ:RDUS)’s key stats reveals a current market capitalization of 1.48 Billion based on 43.19 Million shares outstanding and a price at last close of $36.87 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-03-21, Biotech picked up 50,000 at a purchase price of $35.83. This brings their total holding to 4,540,399 as of the date of the filing.

On the sell side, the most recent transaction saw Ward unload 25,000 shares at a sale price of $62.77. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Radius Health Inc. (NASDAQ:RDUS) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.